Zynex (ZYXI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Zynex (OTCMKTS:ZYXI) announced its quarterly earnings data on Tuesday. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.01, MarketWatch Earnings reports. The business had revenue of $8.13 million for the quarter, compared to the consensus estimate of $7.96 million. Zynex had a net margin of 33.49% and a return on equity of 205.15%.

OTCMKTS:ZYXI traded down $0.04 during trading hours on Wednesday, reaching $3.40. 2,300 shares of the company were exchanged, compared to its average volume of 15,393. Zynex has a 52-week low of $1.10 and a 52-week high of $5.50. The company has a market cap of $104.50 million, a P/E ratio of 15.45 and a beta of 0.95.

A number of equities analysts have weighed in on the stock. ValuEngine downgraded shares of Zynex from a “hold” rating to a “sell” rating in a research note on Tuesday, October 2nd. B. Riley set a $7.00 price target on shares of Zynex and gave the stock a “buy” rating in a research note on Friday, November 2nd. Finally, Zacks Investment Research downgraded shares of Zynex from a “hold” rating to a “sell” rating in a research note on Friday, August 10th.

ILLEGAL ACTIVITY WARNING: “Zynex (ZYXI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.wkrb13.com/2018/11/07/zynex-zyxi-releases-quarterly-earnings-results-beats-estimates-by-0-01-eps.html.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Further Reading: When is a capital gain realized?

Earnings History for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply